Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | GLA | P06280 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31173872 | 0.88 | MAPT (0.50) | ALDH1A1HPGDSMN1; SMN2MAPTCASP3 | |
| SCHEMBL14737303 | 0.88 | MAPT (0.50) | ALDH1A1HPGDSMN1; SMN2MAPTCASP3 | |
| SCHEMBL23248573 | 0.88 | MAP2K4 (0.44) | ALDH1A1HPGDSMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL23559707 | 0.84 | ADORA2A (0.47) | ALDH1A1HPGDSMN1; SMN2MAPTCASP3 | |
| SCHEMBL24337979 | 0.82 | CA12 (0.46) | ALDH1A1HPGDSMN1; SMN2MAPTCASP3 | |
| SCHEMBL7426182 | 0.82 | ALDH1A1 (0.43) | ALDH1A1HPGDSMN1; SMN2MAPTCASP3 | |
| SCHEMBL29950049 | 0.82 | ALDH1A1 (0.43) | ALDH1A1HPGDSMN1; SMN2MAPTCASP3 | |
| SCHEMBL24338456 | 0.82 | GLA (0.44) | ALDH1A1HPGDSMN1; SMN2MAPTCASP3 | |
| SCHEMBL23559702 | 0.82 | KDM4E (0.50) | ALDH1A1HPGDSMN1; SMN2MAPTCASP3 | |
| SCHEMBL29491274 | 0.82 | CA12 (0.46) | ALDH1A1HPGDSMN1; SMN2MAPTCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676929-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2026-01-14 | — | — | EP | disclosed |
| EP-4638447-A1 | IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS | Dark Blue Therapeutics Ltd (GB) | 2025-10-29 | — | — | EP | disclosed |
| US-12358879-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-15 | — | — | US | disclosed |
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | BRIDGE MEDICINES | 2025-05-01 | — | — | US | disclosed |
| CN-115427035-B | ENL/AF9 YEATS inhibitors | 洛克菲勒大学 | 2025-04-22 | — | — | CN | disclosed |
| EP-4046688-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2025-04-09 | — | — | EP | disclosed |
| WO-2024188906-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2024-09-19 | — | — | WO | disclosed |
| EP-4428134-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2024-09-11 | — | — | EP | disclosed |
| WO-2024133560-A1 | IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS | DARK BLUE THERAPEUTICS LTD (GB) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024133560-A1 | IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS | DARK BLUE THERAPEUTICS LTD (GB) | 2024-06-27 | — | — | WO | disclosed |
| CN-111825595-A | Sodium channel blockers | 山东轩竹医药科技有限公司 | 2020-10-27 | — | — | CN | disclosed |
| EP-2120569-B1 | SPIROCHROMANON DERIVATIVES | MERCK SHARP & DOHME (US) | 2013-08-14 | — | — | EP | disclosed |
| US-8138197-B2 | Spirochromanon derivatives | MSD K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-8138197-B2 | Spirochromanon derivatives | MSD K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-8138197-B2 | Spirochromanon derivatives | MSD K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| EP-2120569-A2 | SPIROCHROMANON DERIVATIVES | Merck & Co., Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090270436-A1 | SPIROCHROMANON DERIVATIVES | MERCK SHARP & DOHME LLC | 2009-10-29 | — | — | US | disclosed |
| US-20090270436-A1 | SPIROCHROMANON DERIVATIVES | MERCK SHARP & DOHME LLC | 2009-10-29 | — | — | US | disclosed |
| US-20090270436-A1 | SPIROCHROMANON DERIVATIVES | MERCK SHARP & DOHME LLC | 2009-10-29 | — | — | US | disclosed |
| WO-2008088692-A2 | SPIROCHROMANON DERIVATIVES | MERCK & CO., INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270436-A1 | SPIROCHROMANON DERIVATIVES | AKR1C3, CBR3, AKR1C4 | ALDH1A1 113/4885HPGD 2417/4885SMN1; SMN2 3531/4885 |
| US-12358879-B2 | Heterocyclic compound | PARK7, SMN1; SMN2, SNCA | ALDH1A1 1856/4885HPGD 3186/4885SMN1; SMN2 2/4885 |
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | MLLT3, MLLT1, YEATS2 | ALDH1A1 1756/4885HPGD 4028/4885SMN1; SMN2 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.